Pulmonary Arterial Hypertension (PAH) Market Size, Analysis and Forecast up to 2028
                     Pulmonary Arterial Hypertension (PAH) Market: Introduction
According  to  the  report,  the  global pulmonary  arterial  hypertension  (PAH)  market was
valued at US$ 5.2 Bn in 2020 and is projected to expand at a CAGR of 5.4% from 2021 to
2028. Pulmonary arterial hypertension (PAH) is an uncommon type of progressive illness
linked with high blood pressure. However, prevalence of PAH has increased in the past few
years  due  to  rise  in  risk  factors  such  as  HIV,  sedentary  lifestyle,  tobacco  &  alcohol
consumption, smoking, and other idiopathic conditions.
The available medications to treat PAH can only reduce symptoms, improve the quality of
life,  and slow down disease progression.  Prostacyclin & prostacyclin  analogs,  endothelin
receptor antagonists (ERAs), and phosphodiesterase-5 (PDE-5) inhibitors are the major drug
classes prescribed to patients suffering from PAH.
A study conducted by the World Health Organization and the Centers for Disease Control
and Prevention suggested that the prevalence of PAH is estimated at about 15 to 50 cases
per million, and there is no cure for this disorder in the market. Therefore, the market is
expected to witness strong growth in the near future.
Request a PDF Brochure 
- https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1181
Increase in Global Geriatric Population to Drive Market
The increase in geriatric population in developing countries is projected to propel the global
market  in  the  near  future.  According  to  a  United  Nations  report,  the  global  geriatric
population (people aged 65 years or above) stood at 727 million in 2020. The number is
expected to double to reach 1.5 billion by 2050.
The United Nations Population Fund and HelpAge India statistics state that the number of
elderly people in India is likely to reach to 173 million by 2026. Hence, the incidence of PAH
among the elderly population is projected to increase during the forecast period.
Aging  is  one  of  the  non-modifiable  factors  that  increases  the  risk  related  to  PAH.
Additionally, elderly people are prone to this disease due to diastolic dysfunction and age-
associated blood vessel stiffening. Several educational and awareness programs have been
initiated  by  key  players  and  governments  to  increase  awareness  about  PAH  among
healthcare  providers  and patients.  Several  government  organizations  such  as  the  WHO,
Million  Hearts,  and  others  have  undertaken  initiatives  to  create  awareness  about  PAH.
These factors are expected to boost the growth of the global  market over the next few
years.
Expanding operations in future? To get the perfect launch ask for a custom report
Prostacyclin & Prostacyclin Analogs Segment to Dominate Global Market
Based on drug class,  the global  pulmonary arterial  hypertension (PAH) market has been
classified  into  prostacyclin  &  prostacyclin  analogs,  PDE-5  inhibitors,  ERAs  (endothelin
receptor antagonists), and soluble guanylate cyclase (sGC) stimulators. The prostacyclin &
prostacyclin analogs segment dominated the market in 2020. This can be attributed to high
demand  and  increase  in  incidence.  In  July  2021,  Uptravi  received  FDA  approval  for
intravenous use in pulmonary arterial hypertension patients. The SGC simulators segment is
anticipated to grow at a rapid pace during the forecast period. sGC stimulators can ensure
maximum activation of  sGC by  potentiating  NO-sGC signaling.  Riociguat  (Adempas  from
Bayer) is the only drug approved for PAH in this category. Sales of Adempas grew by over
50% in 2020 compared to 2019, indicating significant demand.
Request a Sample of Pulmonary Arterial Hypertension (PAH) Market: 
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181
North America to Dominate Global Market
In  terms  of  region,  the  global  pulmonary  arterial  hypertension  (PAH)  market  has  been
segmented into  North  America,  Europe,  Asia  Pacific,  Latin  America,  and  Middle  East  &
Africa. North America dominated the global pulmonary arterial hypertension (PAH) market
in 2020, followed by Europe. The market in the two regions is expected to witness strong
growth during the forecast period. This can be attributed to commercialization of new PAH
drugs. Moreover, rise in awareness among the people about availability of treatment for
pulmonary  arterial  hypertension  is  likely  to  augment  the  market  in  North  America  and
Europe.
Enquiry before Buying Pulmonary Arterial Hypertension (PAH) Market Report - 
https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1181
Competition Landscape
The global pulmonary arterial hypertension (PAH) market is fragmented in terms of number
of players. Key players in the global market include Actelion Pharmaceuticals, Ltd., Gilead
Sciences, Inc., GlaxoSmithKline plc, Pfizer, Inc., and United Therapeutics Corporation. These
players  adopt  strategies  such  as  new  product  development  &  commercialization,
distribution  agreements  for  business  expansion,  and  commercial  expansion.  Moreover,
these companies make significant investments in developing products to boost revenue.
More Trending Reports by Transparency Market Research:
Wound Debridement Market- https://www.transparencymarketresearch.com/wound-
debridement-market.html
Ophthalmic Drugs Market- https://www.transparencymarketresearch.com/ophthalmic-
drugs-market.html
Topical Pain Management Therapeutics in Sports Medicine Market- 
https://www.transparencymarketresearch.com/topical-pain-management-therapeutics-
sports-medicine-market.html
Alpha 1 Antitrypsin Deficiency Treatment Market- 
https://www.transparencymarketresearch.com/alpha-1-antitrypsin-deficiency-treatment-
market.html
Sterilization Equipment and Disinfectant Market- 
https://www.transparencymarketresearch.com/sterilization-equipment-market.html
Respiratory Disorders Treatment Market- 
https://www.transparencymarketresearch.com/respiratory-disorders-treatment-
market.html
Cryptococcosis Market- https://www.transparencymarketresearch.com/cryptococcosis-
market.html
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market- 
https://www.transparencymarketresearch.com/non-alcoholic-steatohepatitis-biomarkers-
market.html
About Us 
Transparency  Market  Research,  a  global  market  research  company  registered  at
Wilmington, Delaware, United States, provides custom research and consulting services. The
firm scrutinizes factors shaping the dynamics of demand in various markets. The insights
and  perspectives  on  the  markets  evaluate  opportunities  in  various  segments.  The
opportunities in the segments based on source, application, demographics, sales channel,
and  end-use  are  analysed,  which  will  determine  growth  in  the  markets  over  the  next
decade.
 
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking
insights for thousands of decision-makers, made possible by experienced teams of Analysts,
Researchers, and Consultants. The proprietary data sources and various tools & techniques
we use always reflect the latest trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary and secondary research
techniques in all of its business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit 
subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-
TdDMuODiL8BKQ
Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: [email protected]